Bristol Myers Squibb EVP Sells $1.85M in Shares

David Elkins trims his stake in the pharmaceutical company by 15.8%

Apr. 2, 2026 at 8:54pm

Got story updates? Submit your updates here. ›

An extreme close-up of gears, levers, and other industrial components, conveying the intricate mechanics of the financial system in a visually striking, non-literal manner.A close-up view of the complex inner workings of the financial industry, capturing the tangible machinery that underpins the movement of capital.Princeton Today

Bristol Myers Squibb Company (NYSE:BMY) Executive Vice President David Elkins sold 30,000 shares of the company's stock for a total transaction value of $1,850,100. The sale represented a 15.85% decrease in Elkins' ownership stake in the biopharmaceutical firm.

Why it matters

Insider sales, even for diversification purposes, can sometimes weigh on investor sentiment, as they may signal a lack of confidence in the company's future prospects. However, Elkins still maintains a significant ownership position in Bristol Myers Squibb.

The details

Elkins sold the 30,000 shares at an average price of $61.67 per share. Following the sale, he now directly owns 159,248 shares in the company, valued at approximately $9.8 million. The transaction was disclosed in a filing with the Securities and Exchange Commission.

  • The sale took place on Wednesday, April 1, 2026.

The players

David Elkins

Executive Vice President at Bristol Myers Squibb Company.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

This insider sale, while significant in size, is not necessarily an indication of broader concerns about Bristol Myers Squibb's prospects. Elkins still maintains a substantial ownership stake, and the company continues to advance its pipeline of cancer and immune-mediated treatments.